Features
The Promise of TKIs
Tyrosine kinase inhibitors may represent a new era for treatment of wet AMD and diabetic retinopathy.
By Omar Saeed, MPH, Veeral S. Sheth, MD, MBA, FACS
Second-Generation Anti-VEGF Agents for Neovascular AMD
Newer agents have significantly altered the treatment landscape for nAMD.
By Scott D. Walter, MD, MSc, FASRS, Sharon Fekrat, MD, FASRS
Novel Therapeutics for Neovascular AMD
A variety of new agents aim to reduce treatment burden and preserve vision.
By Justin C. Muste, MD, Katherine E. Talcott, MD, FASRS
Treating Ophthalmic Artery Stenosis in Patients With AMD
A paradigm shift in the understanding of macular disease.
By Mario Saravia, MD, PhD, Pedro Lylyk, MD, Michael W. Calhoun, BSE, et al.
Web Exclusives
Refractive Error Management During Anti-VEGF Therapy
Addressing an overlooked opportunity for vision optimization in patients with DME or wet AMD.
By Eric A. Lovett Jr., BS, MBA, Matthew R. Starr, MD, Jason Hsu, MD, et al.
Addressing Socioeconomic Disparities in Vision-Threatening AMD
Targeted interventions can remove barriers to care.
By Ji Yun Han, BS, Sarishka Desai, BA, Nazlee Zebardast, MD, MSc, FRCSC
Reimagining the Patient Experience With a Streamlined Injection Protocol
Prioritizing patient comfort doesn’t have to come at the cost of efficiency and safety.
By Esther Lee Kim, MD
Departments
Upfront: Spring Is Here
By Diana V. Do, MD
Uveitis Corner: Biosimilars in Noninfectious Uveitis
Many patients show similar outcomes after switching from the originator drug to a biosimilar, but further research is needed.
By Sruthi Arepalli, MD
Coding Q&A: Coding Guidelines for Wet AMD
Proper use of ICD-10-CM codes ensures compliance and prompt payment.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
Clinical Trial Update April 2025
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.